Aktivolabs Secures HIPAA Certification, Unveils US Operations

Aktivolabs has declared HIPAA certification and the opening of its US operations. The firm is on a global mission to avoid chronic illnesses. Enterprises and governments may use the real-time digital health platform to create scalable, evidence-based health and well-being solutions. In December 2022, Aktivolabs received a US$10 million financial injection in a Series A round headed by Mitsui & Co., Ltd., Adaptive financial Partners, and SEEDS Capital, Enterprise Singapore's investment arm. The company's debut in the United States will entail new jobs, new client and partner engagements, and ongoing digital health science and data advances.

“HIPAA, for Aktivolabs, is a validation and testament to our unwavering commitment to upholding the highest standards of data security and privacy,” says Gourab Mukherjee, Co-founder, and CEO of Aktivolabs. Aktivolabs has over half a million paid subscribers, and global clients and partners include Marsh Mercer, AXA, Sunlife, and Dai-ichi. The US market is the largest private healthcare marketplace in the world, where more than 65% is private, creating opportunities for Digital Health companies, such as Aktivolabs, to sell directly to insurers, employers, and governments, as per pharmabiz.

“HIPAA compliance is far more than just regulatory adherence; it is a stamp of data privacy excellence that extends beyond borders, reinforcing Aktivolabs’ global commitment to data security and privacy,” says Hemant Kumar, Chief Operating Officer of Aktivolabs. “Compliance provides a robust shield against risks; we are a resilient and trustworthy company successfully operating in a data-centric and privacy-conscious business environment.” The current product line of Aktivolabs comprises the Aktivo Score, Aktivo Mind, and Glucolife.